ClinicalTrials.gg
Approved for marketingNCT04074512Updated Mar 2, 2026

Copper Histidinate Treatment for Menkes Disease

An expanded access record providing copper histidinate in Menkes Disease, sponsored by Sentynl Therapeutics, Inc.. Approved for marketing at 20 sites in United States. Open to participants aged 0 Years to 6 Years. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by Sentynl Therapeutics, Inc. (part of Zydus Lifesciences Limited) · Expanded access

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Expanded access
Access type
Intermediate-size population
Ages
0 Years to 6 Years
Sex
All
01

Study summary

This expanded access protocol provides subcutaneous copper histidinate for Menkes disease patients under 6 years of age.

02

Conditions studied

  • Menkes Disease
03

In context

Lead sponsor

Sentynl Therapeutics, Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.

First submitted after Sentynl Therapeutics, Inc. became part of Zydus Lifesciences Limited.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Years to 6 Years
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject must have been treated in protocol 09-CH-0059 or must be a newly diagnosed Menkes disease patient in the US.
  2. Parent or legal guardian is willing and able to sign and date an form.
  3. Male or female, aged 0 to \<6 years of age.
  4. Diagnosis of Menkes disease: A confirmed gene mutation in ATP7A is not required; however, the test must be at least pending prior to initiating therapy. For those patients whose molecular ATP7A gene mutation confirmation is pending, they should have serum copper \<75 mcg/dL. If the mutation is subsequently not confirmed, the patient should discontinue treatment.
  5. Ability to adhere to the prescribed subcutaneous copper histidinate injection regimen.
  6. Willingness to adhere to all recommended visits and procedures.
  7. Resident of the US.

Exclusion criteria

Exclusion Criteria

  1. Diagnosis of Wilson disease.
  2. Any disease or condition that, in the opinion of the Investigator, has a high probability of precluding the subject from completing the study or where the subject cannot or will not appropriately comply with study requirements.
  3. Receipt of concomitant medication or device not approved for any use (i.e. experimental) by FDA within 30 days prior to screening for this study, except for participation in protocol 09-CH-0059.
  4. Patient/caregiver cannot or will not appropriately comply with protocol recommendations (e.g., site visits, renal monitoring).
  5. Currently receiving any concomitant copper-containing medications.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Access details

Study type
Expanded access
Access type
Intermediate-size population

Available treatment

  • Drugcopper histidinate

    copper histidinate for subcutaneous injection

    Also known as: CUTX-101

06

Where to request access

20 sites
  • Phoenix Children's Hospital
    Phoenix, Arizona 85016, United States
  • University of California Davis Medical Center
    Sacramento, California 95817, United States
  • Rady Children's Hospital
    San Diego, California 92123, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Connecticut Children's Medical Center
    Hartford, Connecticut 06106, United States
  • Memorial Healthcare Systems
    Hollywood, Florida 33021, United States
  • Johns Hopkins All Children's Hospital
    St. Petersburg, Florida 33701, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • University of Iowa Stead Family Children's Hospital
    Iowa City, Iowa 52242, United States
  • Maine Medical Center
    Portland, Maine 04102, United States
  • Helen DeVos Children's Hospital
    Grand Rapids, Michigan 49503, United States
  • Shodair Children's Hospital
    Helena, Montana 59601, United States
  • Duke University Hospital
    Durham, North Carolina 27710, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Children's Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15224, United States
  • Monroe Carrell Jr. Children's Hospital at Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Cook Children's Health Care System
    Fort Worth, Texas 76104, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
07

References and documents

Related links

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04074512
Responsible party
Sponsor
First posted
Aug 30, 2019
Last update
Mar 2, 2026
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion